Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
This was a retrospective real-world evidence cohort study.
BRAF Positive Metastatic Melanoma
Mean age, Baseline|Number of male patients, Baseline|Race, Baseline|Mean Charlson comorbidity index (CCI) score, Comorbidity was categorized into three grades: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores â‰¥5., Baseline|Eastern Cooperative Oncology Group performance status (ECOG PS), The ECOG scale consists of 4 grades (from 0 to 4) where 0 implies fully active, and 4 implies completely disabled., Baseline|Number of patients with study-related biomarkers, Study-related biomarkers included BRAF and PD1/PDL1 test dates and results., Baseline|Number of metastatic sites, Baseline
Progression-free survival (PFS), PFS was defined as the time from the initiation of a line of therapy until the date of progression or death., 6 months and 1, 1.5, and 2 years|Overall survival (OS), OS was defined as the time from the initiation of a line of therapy until death from any cause., 6 months and 1, 1.5, and 2 years
This was a retrospective real-world evidence cohort study.